Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors

Hadassah Medical Center

Status and phase: Withdrawn; Phase 2; Phase 1

Conditions: Metastatic Solid Tumors

Treatments: Biological: Tumor Cell Vaccine

Study type: Interventional

Funder types: Other

Identifiers

NCT00148993

100798-HMO-CTIL

Details and patient eligibility

About

The goal of this study is to apply allogeneic tumor cell vaccination for immunotherapy in patients with micro-metastatic disease and/or in patients at high risk disease progression. The present study will use allogeneic tumor cell lines for tumor cell vaccines that share MHC determinants with the patient aiming to overcome possible restriction of antigen presentation.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with measurable metastatic disease or disease resistant to chemotherapy or with minimal residual disease at high risk to relapse.

Exclusion criteria

• Karnofsky less than 60%. Unrelated condition requiring the use of any cytotoxic agents or immunosuppressive agents which may interfere with optimal immune response.